Twenty years of follow‐up of aortohepatic conduits in liver transplantation

Dmitriy Nikitin, Linda W. Jennings, Tariq Khan, Edmund Q. Sanchez, Srinath Chinnakotla, Henry B. Randall, Greg J. McKenna, Robert M. Goldstein, Marlon F. Levy, Goran B. Klintmalm – 29 September 2008 – Arterial problems remain a formidable challenge in liver transplantation. In many situations, an aortohepatic conduit can provide a solution. No long‐term results (over 5 years) have been reported.

Quality of life up to 30 years following liver transplantation

Rajendra Desai, Neville V. Jamieson, Alexander E. Gimson, Christopher J. Watson, Paul Gibbs, J. Andrew Bradley, Raaj K. Praseedom – 29 September 2008 – Liver transplantation provides a return to a satisfactory quality of life (QOL) for the majority of patients in the short to medium term (first 5 years), but there is very little information on the QOL in the longer term and the factors influencing it. We therefore undertook a single‐center cross‐sectional analysis to determine QOL in patients 10 or more years after liver transplantation.

Early posttransplant hepatic venous outflow obstruction: Long‐term efficacy of primary stent placement

Gi‐Young Ko, Kyu‐Bo Sung, Hyun‐Ki Yoon, Kyung Rae Kim, Jin Hyoung Kim, Dong Il Gwon, Sung Gyu Lee – 29 September 2008 – Although balloon angioplasty has been accepted as the safe and effective initial treatment to manage hepatic venous outflow abnormalities, it may induce rupture of the fresh anastomosis but also may be ineffective to eliminate various etiologies of venous outflow abnormalities in the early post‐transplant period. Therefore, we performed primary stent placement in 108 patients to treat early‐onset (≤4 weeks) post‐transplant hepatic venous outflow abnormality.

Long‐term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection

Alexander Kuo, Vivian Tan, Billy Lan, Mandana Khalili, Sandy Feng, John P. Roberts, Norah A. Terrault – 29 September 2008 – The long‐term effects of preemptive antiviral therapy on fibrosis progression in liver transplant recipients with hepatitis C virus (HCV) were examined in a cohort of consecutive liver transplant recipients who received preemptive antiviral therapy for 48 weeks (95% were virologic nonresponders). Control patients were transplanted during this same period but did not receive preemptive therapy.

Abnormal neurological features predict poor survival and should preclude liver transplantation in patients with deoxyguanosine kinase deficiency

David P. Dimmock, J. Kay Dunn, Annette Feigenbaum, Anthony Rupar, Rita Horvath, Peter Freisinger, Bénédicte Mousson de Camaret, Lee‐Jun Wong, Fernando Scaglia – 29 September 2008 – Deoxyguanosine kinase (DGUOK) deficiency is the commonest type of mitochondrial DNA depletion associated with a hepatocerebral phenotype. In this article, we evaluate predictors of survival and therapeutic options in patients with DGUOK deficiency.

Improved outcomes in patients with hepatitis C with difficult‐to‐treat characteristics: Randomized study of higher doses of peginterferon α‐2a and ribavirin

Michael W. Fried, Donald M. Jensen, Maribel Rodriguez‐Torres, Lisa M. Nyberg, Adrian M. Di Bisceglie, Timothy R. Morgan, Paul J. Pockros, Amy Lin, Lisa Cupelli, Frank Duff, Ka Wang, David R. Nelson – 26 September 2008 – Treatment response remains suboptimal for many patients with chronic hepatitis C, particularly those with genotype 1 and high levels of viremia. The efficacy of high‐dose regimens of peginterferon alfa‐2a and ribavirin was compared with conventional dose regimens in patients with features predicting poor treatment responses.

Subscribe to